Effect of chronic oral administration of a low dose of captopril on sodium appetite of hypothyroid rats. Influence of aldosterone treatment.
Rats rendered hypothyroid by treatment with methimazole develop an exaggerated sodium appetite. We investigated here the capacity of hypothyroid rats (N = 12 for each group) to respond to a low dose of captopril added to the ration, a paradigm which induces an increase in angiotensin II synthesis in cerebral areas that regulate sodium appetite by increasing the availability of circulating angiotensin I. In addition, we determined the influence of aldosterone in hypothyroid rats during the expression of spontaneous sodium appetite and after captopril treatment. Captopril significantly increased (P<0.05) the daily intake of 1.8% NaCl (in ml/100 g body weight) in hypothyroid rats after 36 days of methimazole administration (day 36: 9.2 +/- 0.7 vs day 32: 2.8 +/- 0.6 ml, on the 4th day after captopril treatment). After the discontinuation of captopril treatment, daily 1.8% NaCl intake reached values ranging from 10.0 +/- 0.9 to 13.9 +/- 1.0 ml, 48 to 60 days after treatment with methimazole. Aldosterone treatment significantly reduced (P<0.05) saline intake before (7.3 +/- 1.6 vs day 0, 14.4 +/- 1.3 ml) and after captopril treatment. Our results demonstrate that, although hypothyroid rats develop a deficiency in the production of all components of the renin-angiotensin-aldosterone system, their capacity to synthesize angiotensin II at the cerebral level is preserved. The partial reversal of daily 1.8% NaCl intake during aldosterone treatment suggests that sodium retention reduces both spontaneous and captopril-induced salt appetite.
Ventura
R R
RR
Departamento de Ciências Fisiológicas, Instituto de Biologia, Universidade Federal Rural do Rio de Janeiro, Seropédica, RJ, Brasil.
Olivares
E L
EL
Passos Junior
D B
DB
Ramalho
M J
MJ
Antunes-Rodrigues
J
J
Reis
L C
LC
D000284:Administration, Oral; D000450:Aldosterone / Q000627:therapeutic use*; D000804:Angiotensin II / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001066:Appetite / Q000187:drug effects*; D002216:Captopril / Q000008:administration & dosage*; D007037:Hypothyroidism / Q000188:drug therapy*; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000378:metabolism; D012982:Sodium, Dietary / Q000008:administration & dosage*
D000806:Angiotensin-Converting Enzyme Inhibitors; D012982:Sodium, Dietary; D000804:Angiotensin II; D000450:Aldosterone; D002216:Captopril; D012964:Sodium; D007703:Peptidyl-Dipeptidase A